{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:11:35Z","timestamp":1784171495871,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.urology.2022.08.042","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T11:40:37Z","timestamp":1664451637000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Financial Toxicity of Nephrolithiasis: The First Assessment of the Economic Stresses of Kidney Stone Treatment"],"prefix":"10.1016","volume":"170","author":[{"given":"Benjamin W.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Labagnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Feiertag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Crivelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean G.","family":"Assimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.08.042_bib0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.12788\/jcso.0239","article-title":"Financial toxicity in cancer care","volume":"14","author":"O'Connor","year":"2016","journal-title":"J Comm Supportive Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.31557\/APJCP.2020.21.2.289","article-title":"Financial Toxicity","volume":"21","author":"Nogueira","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.urology.2022.08.042_bib0003","first-page":"28","article-title":"Financial toxicity associated with treatment of localized prostate cancer. Nature reviews","volume":"17","author":"Imber","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.08.042_bib0004","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/ijgc-2021-002475","article-title":"Evaluating meaningful levels of financial toxicity in gynecologic cancers","volume":"31","author":"Esselen","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.urology.2022.08.042_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.120.017793","article-title":"Financial toxicity in atherosclerotic cardiovascular disease in the united states: current state and future directions","volume":"9","author":"Khera","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.urology.2022.08.042_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-020-00971-6","article-title":"Economic considerations in the management of nephrolithiasis","volume":"21","author":"Roberson","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2022.08.042_bib0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4111\/icu.2017.58.5.299","article-title":"Epidemiology and economics of nephrolithiasis","volume":"58","author":"Ziemba","year":"2017","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.urology.2022.08.042_bib0008","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1523-1755.2005.00599.x","article-title":"Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?","volume":"68","author":"Saigal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.urology.2022.08.042_bib0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ucl.2018.12.011","article-title":"Assessing cost-effectiveness of new technologies in stone management","volume":"46","author":"Bayne","year":"2019","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2022.08.042_bib0010","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00345-017-2003-y","article-title":"The economics of stone disease","volume":"35","author":"Canvasser","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2022.08.042_bib0011","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bju.14991","article-title":"Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years","volume":"125","author":"Geraghty","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.08.042_bib0012","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)","volume":"123","author":"De Souza","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2022.08.042_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2019.11.022","article-title":"Extensive financial hardship among gynecologic cancer patients starting a new line of therapy","volume":"156","author":"Liang","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0014","unstructured":"Bureau TUSC: About the Hispanic population and it's origin: Census.gov"},{"key":"10.1016\/j.urology.2022.08.042_bib0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.04.003","article-title":"Financial toxicity in gynecologic oncology","volume":"154","author":"Bouberhan","year":"2019","journal-title":"Gynecol Oncol,"},{"key":"10.1016\/j.urology.2022.08.042_bib0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2022.08.042_bib0018","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2015.63.2232","article-title":"Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer","volume":"34","author":"Lathan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0019","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2217\/fon-2021-1282","article-title":"Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA","volume":"18","author":"Inguva","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2014.001542","article-title":"Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study","volume":"11","author":"Zafar","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.urology.2022.08.042_bib0021","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0022","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","article-title":"Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action","volume":"4","author":"Bhanvadia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0023","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial Burdens of cancer treatment: a systematic review of risk factors and outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J Nat Compr Cancer Network"},{"key":"10.1016\/j.urology.2022.08.042_bib0024","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/JU.0000000000001423","article-title":"Patient-reported financial toxicity associated with contemporary treatment for localized prostate cancer","volume":"205","author":"Stone","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.08.042_bib0025","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: The COST measure","volume":"120","author":"De Souza","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2022.08.042_bib0026","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41581-020-0320-7","article-title":"Determining the true burden of kidney stone disease","volume":"16","author":"Thongprayoon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.urology.2022.08.042_bib0027","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2009.03.033","article-title":"Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001","volume":"114","author":"Tan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urology.2022.08.042_bib0028","first-page":"1703","article-title":"Health care costs for adolescents and young adults with cancer: a Wisconsin community-based hospital study between 2005 and 2020","volume":"30","author":"Taparra","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urology.2022.08.042_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.juro.2017.10.039","article-title":"Addressing financial toxicity: the role of the urologist","volume":"200","author":"Mossanen","year":"2018","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522008081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522008081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:48:13Z","timestamp":1758768493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429522008081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"alternative-id":["S0090429522008081"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.08.042","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial Toxicity of Nephrolithiasis: The First Assessment of the Economic Stresses of Kidney Stone Treatment","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.08.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}